Clinical Trials on Epilepsia Partialis Continua in Germany

Total 189 results

Ludwig-Maximilians - University of Munich

Terminated

HEAD-Study Optimizing the Treatment of Children With BECTS (HEAD)

Epilepsy, Rolandic

Germany
Universitätsklinikum Hamburg-Eppendorf
Charite University, Berlin, Germany; University of Erlangen-Nürnberg; Vienna... and other collaborators

Recruiting

EASINESS-TRIAL - Enhancing Safety in Epilepsy Surgery

Epilepsy, Temporal Lobe | Amygdalo-Hippocampal Epilepsy

Germany
UNEEG Medical A/S

Recruiting

Evaluation of the 24/7 EEG SubQ System for Ultra Long-Term Recording of Patients With Temporal Lobe Epilepsy

Epilepsy

United States, Germany, United Kingdom
Desitin Arzneimittel GmbH
FGK Clinical Research GmbH

Terminated

EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy

Partial Epilepsy

Germany
Johannes Gutenberg University Mainz
UCB Pharma GmbH

Completed

Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs (STEP-ONE)

Focal Epilepsy

Germany
UCB Pharma

Terminated

Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide (VICTOR)

Epilepsy, Partial

Austria, Germany, Spain
UCB Pharma

Completed

To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

Partial Epilepsies

United States, Poland, United Kingdom, Switzerland, Hungary, Germany, Sweden, Lithuania
Vertex Pharmaceuticals Incorporated

Terminated

A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy

Epilepsy

United States, Germany
Pfizer

Completed

To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.

Epilepsy, Partial

United States, Germany
Eisai GmbH

Completed

ZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions

Focal Epilepsy

Germany
Cyberonics, Inc.

Terminated

Study Comparing Best Medical Practice With or Without VNS Therapy in Pharmacoresistant Partial Epilepsy Patients

Epilepsy | Partial Epilepsy

Canada, Spain, Belgium, France, Germany, Italy, Netherlands, Norway, Sweden, United Kingdom
Eisai Inc.

Completed

A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy

Epilepsy

Australia, France, Poland, Germany, Spain, India, Serbia, Greece, Korea, Republic of, Russian Federation, Taiwan, Hungary, Italy, Sweden, Denmark, Slovakia, United Kingdom, South Africa
Bial - Portela C S.A.

Completed

Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children

Partial Epilepsy in Children and Adolescents

United Kingdom, Spain, Serbia, Italy, Austria, Bosnia and Herzegovina, Croatia, Czechia, France, Germany, Hungary, Malaysia, Moldova, Republic of, Philippines, Poland, Portugal, Romania, Russian Federation, Slovakia, Taiwan, Ukr...
Pfizer

Completed

Pregabalin Open-Label Extension Trial in Patients With Partial Seizures

Epilepsies, Partial | Epilepsy, Complex Partial

Spain, France, Canada, Germany, Italy, Lithuania, Austria, United Kingdom
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy

Epilepsy, Partial

Belgium, Finland, Hungary, Korea, Republic of, Spain, Taiwan, China, Mexico, Singapore, Thailand, Germany, Portugal, Hong Kong, Italy, United Kingdom, Sweden, Slovakia, Estonia, France, Netherlands, Latvia, India, Bulgaria, Norway, Czechia and more
Bial - Portela C S.A.
Sunovion

Completed

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

Partial Epilepsy

United States, Argentina, Germany, France, Belgium, Canada, Italy, Poland, Greece, Brazil, Cyprus
SK Life Science, Inc.

Recruiting

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

Partial Epilepsy

United States, Spain, Korea, Republic of, Germany, Australia, Poland, Hungary
UCB Biopharma S.P.R.L.
PRA Health Sciences

Completed

A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy

Highly Drug-resistant Focal Epilepsy

Belgium, Bulgaria, Germany, Hungary, Netherlands, Spain
UCB Biopharma SRL

Terminated

An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy

Highly Drug-resistant Focal Epilepsy

Belgium, Bulgaria, Germany, Hungary, Netherlands, Spain
GlaxoSmithKline

Completed

Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures

Epilepsy | Epilepsy, Partial

United States, Germany, Korea, Republic of, Chile, India, Russian Federation, Brazil, Ukraine, Puerto Rico, Argentina
SK Life Science, Inc.

Completed

A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Partial Epilepsy

Australia, United States, Korea, Republic of, Germany, Hungary, Serbia, Bulgaria, Czechia, France, Israel, Poland, Romania, Spain, Thailand, Ukraine
SK Life Science, Inc.

Completed

Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Partial Epilepsy

United States, Spain, Korea, Republic of, Serbia, Germany, Bulgaria, Argentina, Australia, Chile, Czechia, Hungary, Mexico, Poland, Russian Federation, Sweden, Thailand, Ukraine
UCB Pharma

Completed

Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures

Epilepsy, Partial

United States, France, United Kingdom, Germany, Belgium, Mexico, Poland, India, Romania, South Africa, Canada, Brazil, Russian Federation, Czech Republic, Hungary, Italy
Xenon Pharmaceuticals Inc.
Novotech Health Holdings Pte. Ltd.

Active, not recruiting

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy (X-TOLE)

Focal Epilepsy

Spain, United States, Ukraine, Canada, United Kingdom, Germany, Georgia, Italy, Moldova, Republic of
UCB Pharma

Completed

A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.

Epilepsy, Partial

United States, France, United Kingdom, Germany, Belgium, Mexico, Poland, Romania, Canada, Brazil, Russian Federation, Argentina, Hungary, Italy, Czechia
Hospices Civils de Lyon

Recruiting

Neurodevelopmental Impact of Epilepsy on Autonomic Function in Dravet Syndrome (AUTONOMIC)

Epilepsy | Dravet Syndrome

Belgium, France, Germany
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

Epilepsy, Partial Seizures | Epilepsy, Primary Generalized Tonic-Clonic Seizures

United States, Korea, Republic of, Taiwan, Lebanon, Singapore, Malaysia, China, Spain, Bulgaria, Czechia, United Kingdom, Israel, Russian Federation, France, Belarus, Belgium, Bosnia and Herzegovina, Germany, Greece, Hungary, India and more
UCB Pharma

Completed

A Study of Brivaracetam in Subjects With Partial Onset Seizures

Epilepsy, Focal

France, Poland, United Kingdom, Belgium, Germany, Spain, Czech Republic, Finland, Netherlands
UCB Pharma GmbH

Completed

Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy (VICTOS)

Focal Epilepsy With and Without Secondary Generalization

Germany, Austria
Novartis Pharmaceuticals

Completed

Pediatric Epilepsy Study

Epilepsy | Epilepsies, Partial

United States, Germany, Brazil, Mexico
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Once-A-Day Pregabalin For Partial Seizures

Epilepsies, Partial | Partial Seizures

United States, Singapore, Malaysia, Hungary, Czechia, India, Hong Kong, Mexico, Thailand, Argentina, Bosnia and Herzegovina, Bulgaria, Germany, Poland, Puerto Rico, Romania, Russian Federation, Serbia
Pfizer

Completed

To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

Seizure Disorder, Partial

Spain, France, Italy, Australia, United Kingdom, Germany, Belgium, Netherlands, Austria, Sweden, Finland, South Africa, Switzerland
Pfizer

Completed

Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

Seizure Disorder, Partial

Australia, Spain, Portugal, United Kingdom, Canada, Belgium, Germany, Poland, Netherlands, Austria
UCB Pharma GmbH

Completed

Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug (VITOBA)

Epilepsies, Partial

Germany
Eisai Inc.

Recruiting

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

Partial-onset Seizures | Pediatric Epileptic Syndrome

United States, Spain, France, Belgium, Czechia, Denmark, Germany
West German Center of Diabetes and Health
Bionorica SE

Completed

Determination of Postprandial Glycemic Responses by Continuous Glucose Monitoring in a Real-World Setting

Postprandial Glucose Response | Glycaemic Index | Continous Glucose Measurement

Germany
University Hospital Schleswig-Holstein
German Research Foundation

Recruiting

Objective EEG Bed Side Assessment of Impaired Conscious Awareness in Epilepsy

Epilepsy, Absence

Germany
UCB Pharma

Completed

Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures (PASS)

Epilepsies, Partial

France, Germany, United Kingdom, Spain, Netherlands
University Hospital Tuebingen

Withdrawn

Pathophysiology Based Therapy of Early Onset Epileptic Encephalopathies (EE)

Seizure, Epileptic

Germany
Eisai Limited

Terminated

Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy

Epilepsy

Australia, Serbia, Germany, Czech Republic, Romania, Estonia, Lithuania, Croatia, Finland, Hungary, Poland, Russian Federation, Ukraine
Zogenix International Limited, Inc., a subsidiary...

Completed

A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome

Dravet Syndrome

United States, France, United Kingdom, Canada, Germany, Netherlands, Spain
Stichting Epilepsie Instellingen Nederland
Epilepsiefonds

Completed

Cardiac Arrhythmias in Dravet Syndrome

Epilepsy

Netherlands, Germany, United Kingdom
Zogenix International Limited, Inc., a subsidiary...

Completed

An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome

Dravet Syndrome

United States, United Kingdom, Spain, Belgium, Italy, Australia, Denmark, Germany, Canada, Japan, Netherlands, France
Zogenix, Inc.
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.

Active, not recruiting

A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

Dravet Syndrome | Epileptic Encephalopathy | Lennox Gastaut Syndrome

United States, Australia, Belgium, Canada, Denmark, France, Germany, Italy, Mexico, Netherlands, Poland, Spain, Sweden, United Kingdom
UCB Pharma

Completed

Effect of Brivaracetam in Photosensitive Epileptic Subjects

Epilepsy

France, Germany
Takeda

Completed

A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

Dravet Syndrome (DS)

China, Canada, France, Hungary, Poland, United States, Spain, Greece, Australia, Brazil, Serbia, Germany, Italy, Japan, Latvia, Netherlands, Ukraine, Russian Federation
Zogenix International Limited, Inc., a subsidiary...

Completed

A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome

Dravet Syndrome | Seizure Disorder

United States, United Kingdom, Australia, Belgium, Canada, Denmark, France, Germany, Italy, Japan, Spain
University Hospital Schleswig-Holstein

Completed

Lacosamid-i.v.-Register (LCM)

Epilepsy With Partial Onset Seizures With or Without Secondary Generalization

Germany
Eisai Limited

Terminated

A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures

Epilepsy

United Kingdom, Germany, Hungary, Switzerland, Italy, Netherlands, Poland
Eisai Limited

Completed

A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

Idiopathic Generalized Epilepsy | Partial Onset Seizures | Generalised Tonic-Clonic Seizures

France, Spain, Italy, Denmark, Germany, Portugal, Russian Federation

Clinical Trials on Epilepsia Partialis Continua in Germany

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations